Get started
Work

A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Year: 2017
Type: article
DOI: 10.1093/annonc/mdx372.001
Authors: I. Vergote, E. Dean, U. Lassen, J. de Bono, Y. Drew, J-P. Machiels, D. Nielsen, H-T. Arkenau, M. Forster, R. Jones, B. Slomovitz, J. Spicer, M. Johnson, N. Cornez, C. Gennigens, B. Fulton, S. Lisby, L. Basse, R. Coleman, D.S. Hong
Institutions: Universitair Ziekenhuis Leuven, The Christie NHS Foundation Trust, Rigshospitalet, Institute of Cancer Research, Royal Marsden Hospital, Freeman Hospital, Herlev Hospital, Gentofte Hospital, Sarah Cannon Research Institute, University College London, Velindre Cancer Centre, University of Miami, Guy's Hospital, King's College London, Sarah Cannon, University of Liège, Centre Hospitalier Universitaire de Liège, Beatson West of Scotland Cancer Centre, Genmab (Denmark), The University of Texas MD Anderson Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Merck KGaA, Novocure, Clovis Oncology, Atara Biotherapeutics, Eisai, PharmaMar, Medac, Genentech, Ignyta
OpenAlex ID: W2762645844
FWCI: 1.292
Cites:
Cited by: 6
Related to: 10